The history and future of short-acting beta2 -agonist therapy in asthma
- PMID: 31702072
- DOI: 10.1111/resp.13727
The history and future of short-acting beta2 -agonist therapy in asthma
Keywords: asthma; beta agonists; therapeutics.
References
REFERENCES
-
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2014. [accessed Sept 2019.] Available from URL: http://www.ginasthma.org/
-
- Beasley R, Pearce N, Crane J, Windom H, Burgess C. Asthma mortality and inhaled beta agonist therapy. Aust. N. Z. J. Med. 1991; 21: 753-63.
-
- Beasley R. A historical perspective of the New Zealand asthma mortality epidemics. J. Allergy Clin. Immunol. 2006; 117: 225-8.
-
- Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N. Engl. J. Med. 1996; 335: 841-7.
-
- Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting β 2-agonists. N. Engl. J. Med. 2018; 378: 2497-505.
LinkOut - more resources
Full Text Sources